3.09k followers • 19 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Intuitive Surgical, Inc.
Boston Scientific Corporation
Smith & Nephew plc
Globus Medical, Inc.
Cardiovascular Systems, Inc.
K2M Group Holdings, Inc.
Mazor Robotics Ltd.
Globus Medical (GMED) delivered earnings and revenue surprises of -5.77% and 0.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Smith & Nephew said revenues have surpassed $5bn for the first time, and it envisages sales increasing this year by up to 4.5 per cent, yet the group faces “additional uncertainty” from the coronavirus outbreak sweeping through Asia. Fourth-quarter revenue for the group that produces joint repair sports medicine rose 8.7 per cent, while for the full year Smith & Nephew generated $5.2bn in sales, up 4.8 per cent from a year earlier. Thursday’s fourth-quarter earnings report is the first under the steerage of Roland Diggelmann, the former Roche Diagnostics boss who stepped into the top role on November 1.
Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
Medtronic is the latest company to announce a potential impact to its financial results from the outbreak which has disrupted supply chains and delayed reopening of factories in China. Although its manufacturing operations in the country were up and running, Medtronic expects a negative impact from a slowdown in medical device procedures in the region. "Given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time," Chief Executive Officer Omar Ishrak said on a conference call.